Dr. Erlanson is co-founder and vice president of chemistry at Carmot Therapeutics, Inc. Dr. Erlanson earned his PhD in chemistry from Harvard University and was an NIH postdoctoral fellow at Genentech. He joined Sunesis Pharmaceuticals at its inception in 1998, where he played a seminal role in developing fragment-based drug discovery technologies. He also honed his medicinal chemistry skills on targets including proteases, phosphatases, and kinases. During his decade at the company, Dr. Erlanson advanced to associate director of medicinal chemistry and led a team of up to ten scientists and research associates working on multiple targets. Dr. Erlanson is an inventor on more than a dozen issued patents and published patent applications. He is also an author of more than two dozen publications, has given more than two dozen presentations at national and international scientific meetings, and is a co-editor of the first book on fragment-based drug discovery.